Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Chris Parker, Sten Nilsson, Daniel Heinrich, +27

New England Journal of Medicine

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

Oliver Sartor, Robert L. Coleman, Sten Nilsson, +18

The Lancet Oncology

UrologyOncologyMedicinePharmacotherapyCastration-resistant Prostate Cancer +6

A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer

Christopher Parker, S. Pascoe, Aleš Chodacki, +5

European Urology

Ra 223Radiation MedicineUrologyRadiation TherapyMedicine +5

Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

Chris Parker, Daniel Heinrich, Joe M. O’Sullivan, +7

European Journal of Cancer

Radiation MedicineUrologyRadiation TherapyMedicineRadium-223 Chloride +6

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial

Christopher Parker, Robert E. Coleman, Oliver Sartor, +26

European Urology

Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.

Chris Parker, Daniel Heinrich, Joe M. O’Sullivan, +16

Journal of Clinical Oncology

Radium-223 ChloridePharmacotherapyOsteoporosisTreatment VerificationInflammatory Arthritis +23

Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).

Chris Parker, Sten Nilsson, Daniel Heinrich, +16

Journal of Clinical Oncology

Cancer ManagementPathologyRadium-223 ChlorideRadiation MedicineOncology +16

Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA).

Oliver Sartor, Daniel Heinrich, Svein Inge Helle, +17

Journal of Clinical Oncology

Radium-223 ChlorideOsteoporosisOrthopaedic SurgeryInflammatory ArthritisBone Disease +23

Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).

Chris Parker, Sten Nilsson, Daniel Heinrich, +16

Journal of Clinical Oncology

Radium-223 ChlorideOsteoporosisOrthopaedic SurgeryBone DiseaseBone Mets +17

Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA).

Oliver Sartor, Daniel Heinrich, Joe M. O’Sullivan, +16

Journal of Clinical Oncology

Cancer ManagementRadium-223 ChloridePharmacotherapyEcog Performance StatusOrthopaedic Surgery +22